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Electrophysiologic actions of pirmenol in dogs 
with recent myocardial infarction 
The electrophysiologic actions of pirmenol, an investigational class I antiarrhythmic agent, were 
evaluated in eight anesthetized dogs, 5 to 10 days after anterior myocardial infarction. Before 
administration of the drug, programmed ventricular stimulation failed to initiate nonsustained or 
sustained ventricular tachyarrhythmias (VT) in any of the postinfarction dogs. After the 
cumulative administration of 2.5, 5.0, and 10.0 mg/kg pirmenol, programmed stimulation initiated 
sustained VT in six of the eight postinfarction dogs tested, with one additional dog responding 
with reproducible nonsustained VT (15 to 20 monomorphic complexes) after pirmenol 
administration. Only one of eight postinfarction dogs tested remained noninducible throughout 
the pirmenol dosing schedule. Administration of pirmenol tended to increase ventricular 
excitation thresholds, relative (p < 0.05 after 10 mg/kg) and effective refractory periods in 
ischemically injured ventricular myocardium, and increased the difference or disparity in relative 
(p < 0.05 after 5.0 and 10.0 mg/kg) and effective (p < 0.01 after 2.5, 5, and 10, mg/kg) 
refractory periods between ischemically injured and normal noninjured ventricular myocardium. 
These findings suggest a potential for the provocation or aggravation of ventricular arrhythmias 
by pirmenol in the setting of recent myocardial infarction. (AM HEART J 1986;112:752.) 
Joseph J. Lynch, Ph.D., Lorenzo A. DiCarlo, M.D., Daniel G. Montgomery, B.S., 
Terek Hassan, B.S., and Benedict R. Lucchesi, Ph.D., M.D., Ann Arbor, Mich. 
The recent increased use of antiarrhythmic drugs 
for the management of potentially serious cardiac 
arrhythmias has developed a greater awareness and 
appreciation of the untoward effects of such agents. 
Clinical studies using ambulatory monitoring in 
conjunction with exercise testing’ or electrophysio- 
logic testing procedures2m4 have indicated that con- 
ventional and investigational antiarrhythmic agents 
possess the potential for aggravating or provoking 
potentially lethal arrhythmias. These findings 
emphasize the need for early detection of potential 
arrhythmogenic actions and investigation of the 
electrophysiologic mechanisms of arrhythmogenic 
activity of such agents to minimize the facilitation of 
arrhythmias in patients. 
During the course of an ongoing evaluation of 
antiarrhythmic agents, a small subset of postinfarc- 
tion dogs that failed to respond to programmed 
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ventricular stimulation with ventricular tachyar- 
rhythmia were prepared. Previously, this laboratory 
reported the use of programmed stimulation testing 
in such nonresponsive postinfarction dogs in an 
investigation of the electrophysiologic actions and 
proarrhythmic potential of lidocaine.5 In the present 
investigation, postinfarction dogs determined to be 
nonresponsive to programmed stimulation testing in 
the pretreatment state were used to evaluate the 
electrophysiologic actions of pirmenol, an investiga- 
tional class I antiarrhythmic agent with demon- 
strated efficacy in experimental arrhythmia models 
of varying etiolo&.* and in preliminary clinical 
evaluations.g-‘2 The results of this investigation sug- 
gest a potential for the facilitation or provocation of 
ventricular tachyarrhythmias by pirmenol in the 
presence of recent ischemic injury, possibly resulting 
from increased refractoriness in ischemically injured 
ventricular myocardium and an increased dispersion 
in refractoriness between normal noninjured and 
ischemically injured ventricular tissue. 
METHODS 
Anterior myocardial infarction. Eight male mongrel 
dogs (14.5 to 21.5 kg) were anesthetized with intravenous 
sodium pentobarbital, 30 mg/kg. The dogs were ventilated 
with room air with the use of a cuffed endotracheal tube 
and a Harvard respirator. Using aseptic technique, the left 
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external jugular vein and left common carotid artery were 
isolated, and cannulae were inserted. A left thoracotomy 
was performed between the fourth and fifth ribs. The 
pericardium was opened and the heart was suspended in a 
pericardial cradle. The left anterior descending coronary 
artery was isolated at the tip of the left atria1 appendage. 
A 1% or 20-gauge hypodermic needle was placed parallel 
to the left anterior descending coronary artery and a 
suture was passed around both the vessel and the needle. 
The suture was tied securely and the needle withdrawn, 
producing a critical stenosis. The artery was then occluded 
using a snare formed from a loop of polymeric silicone 
(Silastic, Dow Corning Midland, Mich.) tubing (Retract- 
O-Tape, Medical Products, Sun Prarie, Wis.) passed 
through a polyethylene tube. Blood flow through the left 
anterior descending coronary artery was restored after 2 
hours. 
An epicardial bipolar electrode (1 mm diameter silver 
electrodes embedded 3 mm apart in acrylic) was sutured 
to the left atria1 appendage for atria1 pacing. A bipolar 
plunge electrode (25-gauge insulated stainless steel wire, 5 
mm in length, 2 mm apart) was sutured into the interven- 
tricular septum for determination of right ventricular 
outflow tract ventricular excitation threshold voltage, 
refractory period, and for the introduction of ventricular 
extrastimuli during programmed stimulation. Silver disc 
electrodes were implanted subcutaneously for monitoring 
the ECG, the surgical incision was closed, and the animals 
were allowed to recover from surgical anesthesia. The 
animals received ampicillin, 10 mg/kg by subcutaneous 
injection twice daily, during their postinfarction convales- 
cence. 
Experimental protocol for electrophysiologic studies 
in the postinfarction dog. Postinfarction dogs were 
returned to the laboratory 5 to 10 days after surgical 
preparation. Initial programmed ventricular stimulation 
testing was performed while the animals were conscious, 
unsedated, and resting comfortably in a sling. Only post- 
infarction dogs that were not susceptible to the initiation 
of ventricular tachycardia during initial programmed 
stimulation testing were entered into the present investi- 
gation. After each animal was determined to be nonre- 
sponsive to programmed ventricular stimulation, it was 
reanesthetized intravenously with Dial (Ciba Pharmaceu- 
tical Co, Summit, N.J.) urethane solution (20% ethylurea, 
20% allobarbital, 0.5”;. urethane, 0.6 ml/kg), ventilated as 
described previously, and the heart was reexposed at the 
fourth left intercostal space via a thoracotomy. With the 
use of Z-gauge hypodermic needles as introducers, one set 
each of bipolar (hook) wire electrodes (Teflon [Du Pont 
Co., Wilmington, Del.]-insulated, 30-gauge silver wire 
with the distal 2 mm tip exposed, 2 mm tip separation) 
was inserted into normal noninfarcted ventricular myo- 
cardium in the proximal left circumflex coronary artery 
distribution, and into ischemically injured ventricular 
myocardium just distal to the site of the left anterior 
descending coronary artery occlusion. The area of anterior 
myocardial infarction was identified visually and through 





Fig. 1. Postinfarction dog model. On day of surgical 
preparation, anterior myocardial infarction is produced by 
2-hour occlusion of left anterior descending coronary 
artery, followed by reperfusion through critical stenosis. 
Broken lines demarcate area at risk of myocardial infarc- 
tion. During surgical preparation, epicardial bipolar elec- 
trode (A) is attached to left atria1 appendage for atria1 
pacing, and bipolar plunge electrode (B) is inserted into 
interventricular septum adjacent to site of occlusion for 
determination of right ventricular outflow tract threshold 
voltage and refractory period, as well as for delivery of 
extrastimuli during programmed ventricular stimulation. 
At time of electrophysiologic testing, bipolar plunge elec- 
trodes are implanted into infarcted ventricular myocardi- 
urn (C) and into normal noninjured ventricular myocardi- 
urn (D) for construction of strength-interval curves. 
normal zone and infarct zone bipolar elect.rodes were used 
to construct ventricular strength-interval curves for the 
determination of ventricular excitability and refractori- 
ness in the two ventricular zones. The essential experi- 
mental features of this preparation are illustrated in 
Fig. 1. 
Sixty minutes after placement of recording electrodes, 
pretreatment programmed ventricular stimulation was 
repeated to confirm the nonresponsiveness of the anesthe- 
tized animal, and electrophysiologic parameters were 
determined in normal noninfarcted and in infarcted ven- 
tricular myocardium. After baseline testing, intravenous 
pirmenol hydrochloride was administered in cumulative 
dosages of 2.5, 5, and 10 mg/kg. The 2.5 and 5 mg/kg 
dosages were administered as lo-minute infusions, while 
the last dosage was infused over a period of 20 minutes. 
Electrophysiologic testing and programmed ventricular 
stimulation were repeated 10 minutes after cessation of 
each of the three drug infusions. 
Measurement of ventricular excitability and refracto- 
riness in normal and infarcted myocardium. Measure- 
ments of ventricular excitability and refractoriness were 
determined through the construction of ventricular 
strength-interval curves at the electrodes sites in normal 
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Table I. Responses to programmed ventricular stimulation 
Pirmenol (m&kg IV) 









2.5 5 10 
NI NSVT NI 
(CL 155) 
SVT SVT* SVT* 
(CL 200) (CL 295/243/250) (CL 300/286/292) 
NI NI SVT 
(CL 238) 
SVT SVT -t 
(CL 178) (CL 200) 
NI NI NI 
NI NI SVT 
(CL 214) 
SVT SVT SVT 
(CL 167) (CL 233) (CL 214) 
NI NI SVT 
(CL 167) 
NI = Noninducible; NSVT = nonsustained ventricular tachycardia; SVT = sustained ventricular tachycardia; CL = ventricular tachycardia cycle length 
expressed in milliseconds. 
*Ventricular tachycardias of various cycle lengths and morphologies were initiated during repeated testing. 
tThe final pirmenol infusion resulted in spontaneous lethal ventricular tachyarrhythmia, which was preceded by a severe reduction in blood pressure. 
noninfarcted and in infarcted ventricular myocardium by 
means of modified previously described methods.13 
Strength-interval curves were constructed at a basic drive 
cycle length of 400 msec (heart rate 150 bpm, 2.5 Hz), with 
the current for the drive beats held constant throughout 
the determination at twice the minimum diastolic thresh- 
old for excitability. During generation of the strength- 
interval relationship, an extrastimulus (S,) was introduced 
into late diastole at a minimum milliamperage (ventricu- 
lar excitation threshold) for eliciting a ventricular 
response (V,). The coupling interval of S, was then 
decreased incrementally until S, failed to elicit a V,. When 
S, failed to elicit a V,, the milliamperage of S? was 
increased until a V, was elicited, and the coupling interval 
was further decreased until S, again failed to elicit a V?. 
The sequence was repeated until a ventricular effective 
refractory period (ERP) was reached at a maximum 
current of 4 mA. The ventricular ERP, therefore, was 
defined as the longest S,-S, interval that failed to elicit a 
V, at 4 mA. The relative refractory period (RRP) was 
defined as the longest S-S, coupling interval along the 
strength-interval curve at which the current required to 
evoke a V, response increased above the diastolic excita- 
tion threshold by greater than 0.025 mA for a 1 msec 
change in coupling interval. 
Programmed ventricular stimulation protocol. Electro- 
cardiographic intervals and electrophysiologic parameters 
were determined immediately before programmed stimu- 
lation testing. Electrocardiographic intervals were deter- 
mined during sinus rhythm. A rate-corrected QT interval 
(QTe = QT in msec/[R-R in set] “) was determined during 
atria1 pacing at 2.5 Hz (model S-44 stimulator, Grass 
Instrument Co., Quincy, Mass.). Right ventricular outflow 
tract excitation threshold voltage and refractory period 
also were determined during 2.5 Hz atria1 pacing. 
During the programmed ventricular stimulation proto- 
col, premature ventricular stimuli (4 msec duration, 
2 X threshold) were introduced into the interventricular 
septum (right ventricular outflow tract, RVOT) using a 
model S-88 stimulator and an SIU-5 stimulus isolation 
unit (Grass Instrument Co.). Single (S,), double (S,S,) and 
then triple (S,S,S,) premature ventricular stimuli were 
introduced. Single ventricular extrastimuli were intro- 
duced during atria1 pacing at S-S, coupling intervals 
decreasing from 350 msec until ventricular refractoriness 
occurred. The RVOT excitation threshold voltage was 
defined as the minimum voltage required to produce a 
conducted ventricular beat (V,) at a stimulus duration of 4 
msec delivered 350 msec after the R wave of the lead II 
ECG. The RVOT refractory period was the longest R to S, 
interval at which a 2 x threshold stimulus failed to 
produce a V, response. Thereafter, double and triple 
ventricular extrastimuli were introduced during sinus 
rhythm at S,-S, and S,-S,-S, coupling intervals of 182,167, 
154,143,133, and 125 msec. Previous work has shown that 
this method fails to produce ventricular dysrhythmias in 
sham-operated animals without previous myocardial is- 
chemic injury.14 
Plasma pirmenol assay. Arterial blood samples were 
obtained immediately before electrophysiologic testing 
and after the cumulative administration of 2.5, 5 and 10 
mg/kg pirmenol. Pirmenol concentrations in plasma were 
determined by the Department of Drug Metabolism and 
Pharmacokinetics at Warner-Lambert/Parke-Davis (Mor- 
ris Plains, N.J.) using a high-performance liquid chro- 
matographic pr0cedure.l” 
Postmortem quantification of myocardial infarct size. 
At the conclusion of each experiment, the hearts were 
excised and cut into 1 cm thick sections from apex to base, 
parallel to the atrioventricular groove. The heart sections 
Volume 112 
Number 4 




Mean arterial pressure (mm Hg) 
PR interval (msec) 
QRS interval (msec) 
QT, interval (msec) (see)-’ 
Paced QT interval (msec) 
Ventricular excitation threshold (V)t 
Ventricular refractory period (msec)t 
*p < 0.05 compared with predrug value. 
tIMermined at the right ventricular outflow tract site. 
119 f 4 
92 f 5 
121 i 4 
61 + 1 
305 f 11 
214 + 7 
1.2 f 0.2 
152 ? 6 
were incubated in 0.5% wt/vol triphenyltetrazolium chlo- 
ride (Sigma Chemical Co., St. Louis, MO.) and phosphate 
buffer (0.1 M, pH 7.4) for 15 minutes. Triphenyltetrazo- 
lium produces a distinctive red when reduced by intracel- 
lular dehydrogenases in viable, noninfarcted tissue. After 
incubation in triphenyltetrazolium, the unstained area of 
infarction was measured as a percentage of total left 
ventricle via gravimetric analysis. 
Drug administration. Pirmenol (Warner-Lambert/ 
Parke-Davis) was provided as a monohydrochloride salt. 
Indicated dosages represent amounts of the base com- 
pound. Normal saline solution (0.9% wt/vol NaCl) was 
used as a vehicle throughout, with the cumulative 10 
mg/kg dose of pirmenol delivered in a total volume of 50 
ml. The drug dosages used in the present study were based 
on the results of previously reported experimental antiar- 
rhythmic evaluations of this agent.6~” 
Statistical analysis. All data are expressed as mean -t 
SEM. Pre- and posttreatment values were compared by an 
analysis of variance for multigroup repeated measures, 
followed by a Dunnett’s test for multiple comparisons to 
one control (pretreatment) group. The criterion for statis- 
tical significance was p < 0.05. 
RESULTS 
Response to programmed ventricular stimulation. 
The responses of postinfarction dogs to programmed 
ventricular stimulation before and after the cumula- 
tive administration of 2.5, 5 and 10 mg/kg pirmenol 
are summarized in Table I. Before pirmenol admin- 
istration, all eight dogs were determined to be 
nonresponsive to programmed ventricular stimula- 
tion in the anesthetized state. In seven of the eight 
dogs, administration of pirmenol in the dosage range 
of 2.5 to 10 mglkg made it possible to initiate 
ventricular tachyarrhythmia (VT) by programmed 
ventricular stimulation using the same pacing proto- 
col used during the predrug testing period. Six of the 
animals responded to postdrug testing with sus- 
tained VTs, with three of six dogs displaying sus- 
tained VT at the initial pirmenol dosage of 2.5 
- 
mg/kg and greater, and the remaining three 
responding with sustained VT only after the admin- 
istration of 10 mg/kg pirmenol. In one of the six 
pirmenol-treated dogs displaying sustained VT, the 
last drug infusion resulted in spontaneous develop- 
ment of lethal ventricular tachyarrhythmia, which 
was preceded by a severe reduction in blood pres- 
sure. Of the two remaining noninducible dogs 
entered into this study, one responded with a repro- 
ducible nonsustained ventricular tachycardia (15 to 
20 monomorphic beats in duration) after the admin- 
istration of 5 mg/kg pirmenol, while the final animal 
remained noninducible throughout the dosing pro- 
tocol (Table I). 
Table II summarizes the pre- and posttreatment 
values for ECG intervals, sinus heart rate, mean 
arterial pressure, and for ventricular excitation 
threshold voltage and refractory period determined 
at the RVOT site. Intravenous pirmenol administra- 
tion to the postinfarction dogs resulted in a progres- 
sive decrease in mean arterial pressure (p < 0.05 at 
10 mg/kg) and increases in both the PR and QRS 
intervals (p < 0.05 at 10 mg/kg). The paced QT and 
rate-corrected QTc intervals were prolonged slight- 
ly, but not significantly, by pirmenol administra- 
tion. 
Electrophysiologic responses in normal noninfarcted 
and in infarcted ventricular myocardium. Before pirme- 
no1 administration, the ventricular excitation 
threshold value determined in infarcted myocardi- 
urn was significantly greater than that of the nonin- 
farcted region, whereas predrug values for the rela- 
tive and effective refractory periods did not differ 
significantly between the two zones. This lack of 
disparity in refractoriness between the infarcted and 
noninfarcted areas of myocardium in the predrug 
setting may reflect the relatively small size of 
infarcted tissue recruited for the construction of the 
strength-interval curves. Administration of intrave- 
nous pirmenol failed to alter values for ventricular 
756 Lynch et al. 
October, 1986 











l NZ 1 t 1 I I 
2.5 5.0 10.0 
PIRMENOL (mg/kg) 
Fig. 2. Effect of pirmenol on ventricular excitation 
threshold (V-ET), effective refractory period (V-ERP), 
and relative refractory period (V-RRP). These values were 
determined before (PRE) and after the cumulative admin- 
istration of 2.5, 5, and 10 mg/kg pirmenol in both normal 
noninfarcted (NZ, solid circles, solid lines) and in infarct- 
ed (IA’, open circles, broken lines) zones of ventricular 
myocardium. Each point represents mean 2 SEM with 
N = 8. tp < 0.05 compared with appropriate PRE values; 
*p < 0.05; **p < 0.01 ZZ value compared with correspond- 
ing NZ value. 
excitation threshold or relative and effective refrac- 
tory periods determined in normal noninfarcted 
myocardium (Fig. 2). During pirmenol infusion, 
excitation thresholds determined in infarcted tissue 
increased in magnitude and variability, while infarct 
zone effective and relative refractory periods 
increased in a dose-dependent fashion, with the 
latter parameter differing significantly (p < 0.05) 
from its predrug value after administration of 10 
mg/kg pirmenol (Fig. 2). Of primary importance was 
the fact that the administration of pirmenol resulted 
in the development of significant differences be- 
tween paired noninfarcted vs. infarcted zone values 
for both the relative refractory period (p < 0.05 after 
5 and 10 mg/kg pirmenol) and the effective refracto- 
ry period (p < 0.01 after 2.5, 5, and 10 mg/kg 
pirmenol), where no such difference or disparity had 
existed before drug administration (Fig. 2). Infarct 
zone values for excitation threshold continued to 
exceed (p < 0.05) paired noninfarct zone values dur- 
ing drug administration (Fig. 2). 
Plasma concentrations of pirmenoi. The cumulative 
administration of 2.5, 5, and 10 mg/kg pirmenol to 
postinfarction dogs resulted in mean plasma pirme- 
no1 concentrations of 1.18 f 0.17, 2.21 +- 0.34, and 
3.36 + 0.55 pg/ml, respectively. Plasma pirmenol 
concentrations achieved in this study ranged from 
0.55 to 6.81 pg/ml. In animal Nos. 2,4, and 7 (Table 
I), sustained VTs were initiated after administration 
of 2.5 mg/kg pirmenol, yielding plasma pirmenol 
concentrations of 1.11 -t 0.16 hg/ml. Sustained VTs 
were initiated in animal Nos. 3, 6, and 8 (Table I) 
after the administration of 10 mg/kg pirmenol, 
yielding plasma pirmenol concentrations of 3.15 + 
0.58 pg/ml. A plasma pirmenol concentration of 6.81 
pg/ml was associated with the development of hemo- 
dynamic compromise and spontaneous lethal 
arrhythmia in animal No. 4 (Table I). 
Postmortem quantification of infarct size. The sizes 
of the underlying anterior myocardial infarcts in the 
eight pirmenol-treated dogs were determined to be 
10.2% f 2.1% of the total left ventricle. In recent 
antiarrhythmic and electrophysiologic evaluations 
in this laboratory, postinfarction dogs that were 
responsive to initiation of VT by programmed ven- 
tricular stimulation using a pacing protocol identical 
to that used in this study possessed anterior infarc- 
tions ranging from 18.9 + 2.0% to 25.6% * 2.6 % of 
the total left ventricle. 16-20 Postinfarction dogs that 
were nonresponsive to the present programmed 
stimulation protocol in two previous evaluations 
possessed anterior infarctions comprising 5.3 % +- 
1.1% and 7.1% f 1.4% of the total left ventricle.18% ‘I 
A previous evaluation of the arrhythmogenic actions 
of lidocaine used dogs with anterior infarctions 
comprising 8.6% * 4.0% of the total left ventri- 
cle.5 
DISCUSSION 
Electrophysiologic testing for the evaluation of 
proarrhythmic drug responses. Clinical investigations 
have advanced the use of programmed ventricular 
stimulation for the systematic evaluation of proarr- 
hythmic responses to antiarrhythmic therapy in 
patients referred for study because of ventricular 
arrhythmias.2-4 Initial studies using programmed 
stimulation techniques have reported overall inci- 
dences of the aggravation or provocation of ventric- 
ular arrhythmias in 13 % to 16 % of conventional and 
investigational antiarrhythmic drug tests3e4 occur- 
ring in 13% to 30% of patients studied.2-4 A similar 
incidence of proarrhythmic response to antiarrhyth- 
mic therapy, 11% of drug tests in 34 % of patients, 
has been demonstrated using ambulatory ECG mon- 
itoring and exercise testing.l Programmed ventricu- 
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lar stimulation testing, therefore, may predict 
proarrhythmic drug responses with an overall inci- 
dence approximating that reported by ambulatory 
monitoring techniques and offers the advantages of 
less variability in response and earlier detection of 
potential proarrhythmic actions. Electrophysiologic 
testing additionally permits a more thorough evalu- 
ation of the mechanism sof proarrhythmic action of 
antiarrhythmic agents, which should result ulti- 
mately in the development of antiarrhythmic thera- 
pies with minimal proarrhythmic potential. 
Effects of pirmenol on the response to programmed 
ventricular stimulation. In the present study, the 
electrophysiologic actions of intravenous pirmenol 
were evaluated in dogs with recent myocardial 
infarction but nonresponsive to programmed ven- 
tricular stimulation testing in the pretreatment set- 
ting. After the cumulative administration of 2.5 to 
10 mg/kg pirmenol, programmed pacing techniques 
identical to those used in the pretreatment setting 
initiated sustained VTs in six of eight postinfarction 
dogs tested, with one additional animal responding 
to programmed stimulation with nonsustained ven- 
tricular tachycardia after pirmenol. Pirmenol facili- 
tated the initiation of ventricular tachycardia in 
postinfarction dogs with underlying anterior myo- 
cardial infarcts markedly smaller in size than those 
found in inducible postinfarcted dogs in previous 
investigations in this laboratory.‘6-20 Additionally, 
the rates of the VTs initiated in the pirmenol- 
treated dogs tended to be slower than those initiated 
in inducible postinfarction dogs during pretreat- 
ment testing in previous studies.‘6-‘” The pirmenol 
plasma concentrations achieved in the present 
investigation were comparable to those determined 
effective in the suppression of spontaneous ventric- 
ular ectopy in dogs 24 to 48 hours after experimental 
myocardial infarction’ and in reducing the frequen- 
cy of premature ventricular contractions in patients 
with chronic ventricular ectopy.g-‘” 
Clinical arrhythmogenic aspects of pirmenol. Prelim- 
inary clinical trial data have shown the incidence of 
arrhythmogenic responses to pirmenol to be mini- 
mal.* In one multicenter oral dose-response study, 
where 92% of the patients had cardiac disease, the 
incidence of reported arrhythmogcnic responses 
during the double-blind period was less than 2% 
(three of 148 pirmenol treated patients). Two of 
these three patients were titrated with higher pirme- 
no1 doses in the open-label period with beneficial 
results and an absence of side effects. In a multicent- 
er noncomparative study in patients with a history 
of sustained VT or symptomatic nonsustained VT 
followed by electrophysiology assessment, the inci- 
dence of arrhythmogenic responses after intrave- 
nous pirmenol was 6% (five of 89 tested patients) 
whereas 19% of the patients were noninducible. A 
multicenter study is in progress in which intrave- 
nous pirmenol is being compared with intravenous 
lidocaine for the treatment of warning ventricular 
arrhythmias subsequent to acute myocardial infarc- 
tion. While the study is double-blind, early findings 
(n = 30 patients) suggest that pirmenol is at least as 
effective as lidocaine with fewer side effects in this 
setting. No arrhythmogenic responses have been 
reported to date in the conduct of this trial. 
Electrophysiologic actions of pirmenol. In VitrO 
studies in canine Purkinje fibers have shown pirme- 
no1 to decrease action potential amplitude and 
upstroke velocity (Vm,,), shorten the action potential 
duration (APD,,), increase the effective refractory 
period, and depress membrane responsiveness in a 
manner similar, but not identical, to currently avail- 
able “local anesthetic” class I antiarrhythmic 
agents.2” Pirmenol’s ability to depress the rate of 
cellular depolarization (VjmaX, a cellular correlate for 
conduction velocity at the tissue level) would be 
consistent with the prolongation in the QRS dura- 
tion observed after the 10 mg/kg drug dosage by 
virtue of a depression in ventricular conduction 
velocity. A class I type depression in ventricular 
conduction also might account for the relatively 
slower rates of ventricular tachycardia initiated in 
the pirmenol-treated dogs in this study. 
Previous investigators have speculated that a 
basic electrophysiologic mechanism underlying the 
abilities of antiarrhythmic agents to aggravate or 
provoke ventricular arrhythmias is a critical slowing 
in ventricular conduction (i.e., delayed activation 
times) with only minimal increases in refractoriness 
in potential reentrant pathways, thereby facilitating 
the development of reentrant VTs.] Patterson et 
a1.5 demonstrated that selective increases in activa- 
tion delays and refractoriness in ischemically 
injured ventricular myocardium occur concomitant- 
ly with the facilitation of ventricular tachycardia 
initiation by lidocaine in postinfarction dogs. In the 
present study, pirmenol similarly increased refracto- 
riness selectively in ischemically injured myocardi- 
urn and increased the disparity in refractoriness 
between normal noninjured and ischemically 
injured myocardium. A depression in ventricular 
conduction through a class I-type electrophysiologic 
action, in conjunction with a selective increase in 
refractoriness in ischemically injured ventricular 
758 Lynch et al. 
tissue, may contribute to the ability of pirmenol and 
similar conventional and investigational class I anti- 
arrhythmic agents to facilitate the development of 
VTs in the presence of recent ischemic injury. 
Conctusions. The initiation of VT by programmed 
ventricular stimulation was facilitated by pirmenol, 
an investigational class I antiarrhythmic agent, in 
seven of eight previously noninducible postinfarc- 
tion dogs tested. Pirmenol tended to increase refrac- 
toriness selectively in ischemically injured ventricu- 
lar myocardium and significantly increased the dif- 
ference or dispersion of refractoriness between nor- 
mal noninjured and ischemically injured tissue. The 
results suggest a potential for the aggravation or 
provocation of ventricular arrhythmias by pirmenol, 
as well as similar conventional and investigational 
class I antiarrhythmic agents, in the presence of 
recent ischemic injury. 
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